Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Key Points Nilotinib induced deeper molecular responses than continued imatinib in patients with minimal residual disease on long-term imatinib. These deeper responses may enable more patients to benefit from treatment-free remission trials.

authors

  • Hughes, Timothy P
  • Lipton, Jeffrey H
  • Spector, Nelson
  • Cervantes, Francisco
  • Pasquini, Ricardo
  • Clementino, Nelma Cristina D
  • Dorlhiac Llacer, Pedro Enrique
  • Schwarer, Anthony P
  • Mahon, Francois-Xavier
  • Rea, Delphine
  • Branford, Susan
  • Purkayastha, Das
  • Collins, LaTonya
  • Szczudlo, Tomasz
  • Leber, Brian

publication date

  • July 31, 2014

has subject area

published in